Genmab ASMEX:GMABN 92 Quick Ratio is 2.17 as of Mar. 2026, which is 83% below its 10-year median of 13.08. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Genmab AS ranks worse than 63.7% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Genmab AS's quick ratio for the quarter that ended in Mar. 2026 was 2.17.
Genmab AS has a quick ratio of 2.17. It generally indicates good short-term financial strength.
The historical rank and industry rank for Genmab AS's Quick Ratio or its related term are showing as below:
MEX:GMABN'
s Quick Ratio Range Over the Past 10 Years
Min: 2.01 Med: 13.08 Max: 23.99
Current: 2.17
During the past 13 years, Genmab AS's highest Quick Ratio was 23.99. The lowest was 2.01. And the median was 13.08.
MEX:GMABN's Quick Ratio is ranked worse than 63.7% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs MEX:GMABN: 2.17
Genmab AS (MEX:GMABN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Genmab AS Quick Ratio Related Terms
Genmab AS Quick Ratio Historical Data
* Premium members only.
The historical data trend for Genmab AS's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Genmab AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Genmab AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (MEX:GMABN) has a Quick Ratio of 2.17 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Genmab AS and its competitors. This is 83% below median its historical median of 13.08. Over the past decade, Genmab AS's Quick Ratio has ranged from 2.01 to 23.99. According to the industry distribution chart, Genmab AS ranks #902 out of 1416 companies in the Biotechnology industry, placing it in the top 63.7%.
Is Genmab AS's Quick Ratio too high?
Genmab AS's current Quick Ratio of 2.17 is 83% below median its 10-year median of 13.08. Over the past 10 years, this metric has ranged from a low of 2.01 to a high of 23.99. The Biotechnology industry median Quick Ratio is 3.60. Genmab AS's value of 2.17 is 39.7% below this industry median. Based on the distribution chart, Genmab AS ranks #902 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #902 out of 1416 companies for Quick Ratio. This places Genmab AS in the lower half of its industry. The industry median Quick Ratio is 3.60. Genmab AS's value of 2.17 is 39.7% below this benchmark. Historically, Genmab AS's own Quick Ratio has ranged from 2.01 to 23.99 over the past decade. While the company's 10-year median is 13.08 vs. the industry median of 3.60, Genmab AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Quick Ratio of 2.17 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Quick Ratio is 2.17, which is 83% below median its own 10-year median of 13.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Quick Ratio is 2.17, which is 83% below median its 10-year median of 13.08 and 39.7% below the Biotechnology industry median of 3.60. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Quick Ratio is 2.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Quick Ratio: 2.17 (83% below median its 10-year median of 13.08)
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
Industry Position: 39.7% below the Biotechnology median (#902 of 1416)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
